Clover Health Investments (CLOV) Stock Overview
Provides medicare advantage plans in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CLOV Community Fair Values
Create NarrativeSee what 85 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Clover Health Investments, Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.98 |
| 52 Week High | US$4.23 |
| 52 Week Low | US$1.58 |
| Beta | 2.45 |
| 1 Month Change | 46.86% |
| 3 Month Change | 99.00% |
| 1 Year Change | 25.55% |
| 3 Year Change | 286.41% |
| 5 Year Change | -66.61% |
| Change since IPO | -60.98% |
Recent News & Updates
Recent updates
Seeking Alpha • May 20
Clover Health's Bullish Setup Still Looks Compelling
Summary Clover Health Investments, Corp. (CLOV) is executing a credible turnaround, reporting its first-ever positive GAAP net income and strong Q1 2026 results. CLOV’s Medicare Advantage membership surged 51% YoY with over 95% retention, driving improving cohort profitability and robust gross margins. Disciplined SG&A management and a quality edge, evidenced by a top HEDIS score, support margin expansion and Star rating sustainability. I maintain a Strong Buy rating; risk/reward remains compelling as profitability, cost control, and SaaS upside could drive further multiple expansion. Read the full article on Seeking Alpha
Narrative Update • May 04
CLOV: Interoperability Progress And Execution Efforts Will Shape Balanced Future Outlook
Analysts have reduced their price target on Clover Health Investments by $0.50. This change reflects updated views on its projected revenue growth, profit margin, discount rate, and future P/E assumptions.
Narrative Update • Apr 18
CLOV: Interoperability Progress And 2026 Guidance Will Support Earnings Breakthrough Potential
Analysts have trimmed their price target on Clover Health Investments by $0.50, citing updated assumptions around fair value, price-to-earnings expectations, revenue growth, and profit margin as the key drivers of the change. Analyst Commentary Recent commentary around Clover Health Investments has centered on how updated assumptions about fair value and P/E expectations feed into the new price target, even with the trim of $0.50.Narrative Update • Apr 03
CLOV: CMS Network Interoperability And Execution Improvements Will Support Future Upside
Analysts have trimmed their price target on Clover Health Investments by $0.50. This reflects updated views on fair value and future P/E assumptions following recent research.Narrative Update • Mar 20
CLOV: CMS Network Interoperability Progress Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Clover Health Investments from $3.23 to $2.98. This change reflects updated assumptions around revenue growth, profit margins, and future P/E expectations that inform their latest price target analysis.Narrative Update • Mar 05
CLOV: Patient Data Network Milestone Will Support Earnings Breakthrough Potential
The updated analyst price target for Clover Health Investments has moved from $5.00 to $3.70, as analysts adjust their views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Clover Health announced a collaboration that makes it the first payer live on a CMS Aligned Network and TEFCA for patient directed data requests, using standardized FHIR (USCDI v3) formats for real time exchange of clinical and claims data (Key Developments).Narrative Update • Feb 19
CLOV: Higher Future P/E Assumptions Will Support Further Upside Potential
Analysts have adjusted their price target on Clover Health Investments to $3.23, a change they link to updated assumptions around the discount rate, profit margin, revenue growth, and a future P/E of about 79.19x. Valuation Changes Fair Value: Model fair value is unchanged at $3.23 per share.
Narrative Update • Feb 05
CLOV: Medicare Advantage Expansion And Buybacks Will Support Long-Term Upside
Analysts have raised their price target on Clover Health Investments to US$3.00 from US$3.00. The revision is based on updated views on revenue growth, profit margin, and a slightly lower assumed future P/E multiple, which together refine their assessment of the stock's risk and return trade off.Narrative Update • Jan 22
CLOV: Faster Insurance Outlook And Higher Future P/E Will Support Upside
Analysts have nudged their price targets on Clover Health Investments higher to reflect updated assumptions around slightly faster revenue growth and a modestly higher future P/E near 78x, even as projected profit margins are now described as somewhat lower than before. What's in the News Clover Health Investments reported on its share repurchase activity, stating that from July 1, 2025 to September 30, 2025 it bought back 0 shares for $0m, while completing a total repurchase of 6,907,732 shares, or 1.38%, for $5.36m under the buyback announced on May 7, 2024 (Key Developments).Narrative Update • Jan 07
CLOV: Medicare Advantage Expansion And AI Platform Will Drive Long-Term Upside
Analysts have raised their price target on Clover Health Investments from US$2.50 to US$3.00. They point to updated assumptions for revenue growth, profit margin and future P/E, along with a slightly higher discount rate, as the key drivers of the change.Narrative Update • Dec 22
CLOV: Expanded 2026 Benefits And AI Care Platform Will Drive Upside
Analysts have modestly raised their price target on Clover Health Investments to reflect a slightly improved outlook for revenue growth and long term profitability, now valuing the shares at approximately 3.23 dollars per share. What's in the News Raised full year 2025 insurance revenue guidance to a range of 1.85 billion to 1.88 billion dollars, implying roughly 39% year over year growth at the midpoint compared with the prior outlook of 1.80 billion to 1.875 billion dollars (Corporate Guidance).Narrative Update • Dec 08
CLOV: Expanded 2026 Plan Benefits And AI Care Platform Will Drive Upside
Analysts have modestly revised their price target on Clover Health Investments upward to approximately $3.23 per share. This reflects slightly improved expectations for long term revenue growth and profitability while maintaining a cautious view on the stock's elevated future valuation multiples.Narrative Update • Nov 24
CLOV: Expanding AI Adoption And New Plan Features Will Drive Member Value
Analysts have slightly lowered their price target for Clover Health Investments from $3.23 to $3.23 per share, citing marginal adjustments in future profit expectations and discount rates. What's in the News Raised full-year 2025 earnings guidance, expecting Insurance revenue of $1.85 to $1.88 billion, a 39% year-over-year growth at the midpoint (Key Developments) Unveiled 2026 Medicare Advantage offerings with continued emphasis on affordable, high-choice PPO plans and stable or improved benefits for all members (Key Developments) Maintained four core plan features: affordability, flexibility, predictability, and value, including benefits such as dental, vision, hearing, and fitness at no extra cost (Key Developments) Expanded use of the AI-powered Clover Assistant platform, helping doctors identify and manage chronic diseases like diabetes and kidney disease earlier, benefiting patient outcomes (Key Developments) Launched a multi-phase Availity initiative to improve provider operational efficiency, including centralized access, faster authorizations, and real-time claims tracking (Key Developments) Valuation Changes Consensus Analyst Price Target remains virtually unchanged at $3.23 per share.Narrative Update • Nov 10
CLOV: Insurance Revenue Outlook And Care Coordination Will Drive Share Gains
Analysts have revised their price target for Clover Health Investments downward from $3.37 to $3.23 per share, citing updated financial projections as well as a moderated outlook on profit margins and growth rates. What's in the News Clover Health Investments raised its full-year 2025 earnings guidance, now projecting insurance revenue of $1.850 billion to $1.880 billion.Analysis Article • Nov 05
Further Upside For Clover Health Investments, Corp. (NASDAQ:CLOV) Shares Could Introduce Price Risks After 36% Bounce
Despite an already strong run, Clover Health Investments, Corp. ( NASDAQ:CLOV ) shares have been powering on, with a...Narrative Update • Oct 27
Margin Pressures and Healthcare Reforms Will Influence Future Medicare Advantage Dynamics
Clover Health Investments’ average analyst price target has shifted modestly, rising from $3.20 to $3.37 per share. Analysts weighed solid revenue and membership growth against increased insurance benefit expenses in their latest assessments.Narrative Update • Oct 13
Technology Adoption And Medicare Advantage Will Shape Healthcare's Future
The analyst price target for Clover Health Investments has been revised downward from $3.65 to $3.20 per share. Analysts cite higher-than-expected insurance benefit expenses, which have offset otherwise solid growth and profitability metrics.Analysis Article • Sep 08
A Piece Of The Puzzle Missing From Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Share Price Climb
Clover Health Investments, Corp. ( NASDAQ:CLOV ) shareholders are no doubt pleased to see that the share price has...Narrative Update • Aug 07
Technology Adoption And Medicare Advantage Will Shape Healthcare's Future
Clover Health Investments' consensus price target has declined, as the company's lower future P/E suggests moderated growth expectations despite an improvement in net profit margin, resulting in a revised fair value of $4.31. What's in the News Launched a community-based pharmacy pilot program in New Jersey with IPC Digital Health, aiming to improve medication management for seniors through local pharmacies and AI-powered tools.Analysis Article • May 09
Clover Health Investments, Corp. (NASDAQ:CLOV) Could Be Riskier Than It Looks
It's not a stretch to say that Clover Health Investments, Corp.'s ( NASDAQ:CLOV ) price-to-sales (or "P/S") ratio of...Analysis Article • May 09
Analysts Are Updating Their Clover Health Investments, Corp. (NASDAQ:CLOV) Estimates After Its First-Quarter Results
It's been a pretty great week for Clover Health Investments, Corp. ( NASDAQ:CLOV ) shareholders, with its shares...
New Narrative • Apr 25
Tech-Driven Care And Home Services Will Secure Long-Term Success
Enhanced star ratings will increase future revenue and provide long-term stability due to improved financial benchmarks.Seeking Alpha • Mar 07
Clover Health: Expected Margin Contraction Is A Prelude To Exponential Growth
Summary Clover Health Investments’ AI capabilities are a major driver for its topline and bottom-line improvements in FY 2024. Clover Health’s MCR in Q4 represented a decline from Q3, unlike past years, and rivaled its Q2 MCR, a sign of the impact of its AI capabilities. While Clover expects its margins to contract in FY 2025, its increased investments this year set it up for a highly profitable future starting from FY 2026, in my opinion. I’m reiterating my buy rating for CLOV stock with a price target of $4.9, representing 34% upside from its current valuation. Read the full article on Seeking AlphaAnalysis Article • Feb 25
We Think Clover Health Investments (NASDAQ:CLOV) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jan 16
Clover Health: Undervalued Turnaround Play With Promising SaaS Potential
Summary Clover Health's revenue rose 8% in Q3 2024, driven by a 7% growth in Medicare Advantage premiums, despite exiting low-margin ACO REACH program. Cost control measures are paying off, with salaries and benefits down 9%, general expenses down 14%, and losses narrowing significantly. Strong cash reserves of $287.9 million and no long-term debt provide a safety net for strategic investments, particularly in the Clover Assistant platform. Market undervalues Clover's potential, focusing on short-term revenue drops, but the SaaS model and AI-driven Clover Assistant could drive long-term profitability. Read the full article on Seeking AlphaSeeking Alpha • Dec 21
Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Summary Clover Health's recent performance shows mixed results, with revenue growth but a significant share price drop, presenting a potential buying opportunity. Operational efficiency is improving, with better adjusted EBITDA and reduced net loss, indicating progress towards profitability. Wall Street remains optimistic, with positive ratings and a potential 46% upside, bolstered by a Medicare Advantage PPO plan upgrade. Sector risks include potential regulatory changes and competition, but Clover's innovative products and strong balance sheet offer cautious optimism. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Clover Health: Buy The Dip, Reap The Rewards
Summary Clover Health’s 32% dip following its Q3 earnings could be an opportunity to accumulate shares. Clover continues to grow its top line and improve its bottom-line performance. Clover’s latest star rating upgrade to 4 stars for the payment year 2026 could help it increase its market share and secure more deals for Counterpart Assistant. I’m reiterating my buy rating for CLOV stock with a price target of $4.16, implying a 37% upside from current levels. Read the full article on Seeking AlphaAnalysis Article • Nov 08
Clover Health Investments, Corp. (NASDAQ:CLOV) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
It's been a mediocre week for Clover Health Investments, Corp. ( NASDAQ:CLOV ) shareholders, with the stock dropping...Seeking Alpha • Nov 06
Clover Health's Rally: The Payoff Of A Profitable Pivot
Summary Clover Health's pivot to profitability over growth following the divestiture of the non-insurance segment at the end of 2023 has led to significant earnings improvements. The newly launched Counterpart Health platform could diversify the company's revenue, offsetting risks from declining Medicare Advantage memberships. The company has a strong balance sheet with no long-term debt and high liquidity ratios. Regulatory changes to Medicare Advantage reimbursements and the decline in MA memberships remain key risks to monitor. The recent closure of the SEC investigation without enforcement actions has led to an improvement in investor confidence, reinforcing my strong buy rating. Read the full article on Seeking AlphaAnalysis Article • Oct 03
There's Reason For Concern Over Clover Health Investments, Corp.'s (NASDAQ:CLOV) Massive 37% Price Jump
Clover Health Investments, Corp. ( NASDAQ:CLOV ) shares have continued their recent momentum with a 37% gain in the...Seeking Alpha • Oct 03
Clover Health: Changing Business Model, Seeking Profitability
Summary Clover Health specializes in aiding Medicare physicians with early chronic disease management through its proprietary cloud-based software, Clover Assistant. After years of unprofitability, a change in its business model has led to the first profitable quarter. Despite the turnaround, I argue that Clover Health stock seems fairly priced. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Clover Health: A Profitable Future Ahead Fueled By AI And Star Rating Success
Summary Clover Health Investments posted its first profitable quarter as a public company and raised its full-year guidance in Q2. Clover Health’s star rating increased by 0.5 stars, which could have a positive impact on future top line and bottom line growth. Clover Health’s star rating increase is a testament to the effectiveness of Clover Assistant, which could drive demand for the platform, in my opinion. I’m reiterating my buy rating for CLOV stock and raising my price target to $4.73 per share, representing 88% upside from its current valuation. Read the full article on Seeking AlphaAnalysis Article • Aug 14
Clover Health Investments, Corp. (NASDAQ:CLOV) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Clover Health Investments, Corp. ( NASDAQ:CLOV ) shares have been powering on, with a...Analysis Article • Aug 06
Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Jun 12
Clover Health Investments, Corp.'s (NASDAQ:CLOV) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Clover Health Investments, Corp. ( NASDAQ:CLOV ) shareholders have had their patience rewarded with a 26% share price...Shareholder Returns
| CLOV | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 12.1% | -1.3% | 1.6% |
| 1Y | 25.6% | 12.5% | 28.2% |
Return vs Industry: CLOV exceeded the US Healthcare industry which returned 12.5% over the past year.
Return vs Market: CLOV underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| CLOV volatility | |
|---|---|
| CLOV Average Weekly Movement | 8.8% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLOV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLOV's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 724 | Andrew Toy | www.cloverhealth.com |
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases.
Clover Health Investments, Corp. Fundamentals Summary
| CLOV fundamental statistics | |
|---|---|
| Market cap | US$2.10b |
| Earnings (TTM) | -US$56.94m |
| Revenue (TTM) | US$2.21b |
0.9x
P/S Ratio-36.8x
P/E RatioIs CLOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLOV income statement (TTM) | |
|---|---|
| Revenue | US$2.21b |
| Cost of Revenue | US$1.80b |
| Gross Profit | US$405.75m |
| Other Expenses | US$462.70m |
| Earnings | -US$56.94m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 18.36% |
| Net Profit Margin | -2.58% |
| Debt/Equity Ratio | 0% |
How did CLOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 15:30 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clover Health Investments, Corp. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Fischbeck | BofA Global Research |
| Richard Close | Canaccord Genuity |
| Jason Cassorla | Citigroup Inc |